Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.66 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.66 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 10/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888236 | 0.89 | KCNH2 (0.60) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2887493 | 0.88 | KCNH2 (0.68) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2886588 | 0.85 | KCNH2 (0.66) | KCNH2SCN5ACACNA1IGRM2CYP3A4 | |
| SCHEMBL2881719 | 0.85 | KCNH2 (0.66) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2889555 | 0.84 | KCNH2 (0.65) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2889729 | 0.82 | KCNH2 (0.61) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2887349 | 0.80 | KCNH2 (0.60) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2888295 | 0.80 | KCNH2 (1.00) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL20328171 | 0.80 | KCNH2 (1.00) | KCNH2SCN5ACACNA1IGRM2HTR4 | |
| SCHEMBL2881451 | 0.80 | KCNH2 (0.59) | KCNH2SCN5ACACNA1IGRM2HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | claimed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | claimed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | claimed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | KCNH2 38/4885SCN5A 122/4885CACNA1I 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.